Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.
View Top Employees from Madrigal PharmaceuticalsWebsite | https://www.madrigalpharma.com/ |
Ticker | MDGL |
Revenue | $7 million |
Funding | $3.4 million |
Employees | 430 (142 on RocketReach) |
Founded | 2016 |
Address | 200 Barr-Harbor Dr Suite 200, Conshohocken, Pennsylvania 19428, US |
Phone | (484) 380-9263 |
Technologies |
JavaScript,
HTML,
PHP
+22 more
(view full list)
|
Industry | Pharmaceuticals, Pharmaceutical Manufacturing, Biotechnology, Healthcare, Science and Engineering, Drug Discovery, Medical Device, Health Care, Pharmaceutical |
Keywords | Liver Disease |
Competitors | Alzheon, Inc. | Preserving Future Memories, CymaBay Therapeutics, Galmed Pharmaceuticals Ltd., Metacrine, Inc., Minerva Neurosciences |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Madrigal Pharmaceuticals employee's phone or email?
The Madrigal Pharmaceuticals annual revenue was $7 million in 2024.
Alex Howarth is the CFO of Madrigal Pharmaceuticals.
142 people are employed at Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals is based in Conshohocken, Pennsylvania.
The NAICS codes for Madrigal Pharmaceuticals are [325, 3254, 32541, 32].
The SIC codes for Madrigal Pharmaceuticals are [283, 28].